PROCEPT BioRobotics Faces Securities Fraud Lawsuit Over Inflated Sales

A securities fraud class action lawsuit has been filed against PROCEPT BioRobotics Corporation and several senior executives in the U.S. District Court for the Northern District of California. The litigation, captioned Operating Engineers Construction Industry and Miscellaneous Pension Fund v. PROCEPT BioRobotics Corporation, et al., alleges the company engaged in fraudulent activity between February 28, 2024, and February 25, 2026.

The complaint alleges that the company utilized an undisclosed discount program to incentivize customers to place bulk orders of surgical handpieces that exceeded actual procedure demand. This practice reportedly pulled forward sales from future periods to artificially inflate U.S. handpiece unit sales and revenues, creating a field inventory glut of more than 10,000 excess units by the end of the class period.

These actions allegedly led to materially overstated representations regarding system utilization and sales, rendering the company's 2025 revenue guidance unachievable. The resulting revelations caused significant stock price volatility, including an 18% decline between February 26 and 27, 2026. Several law firms, including The Rosen Law Firm, Levi & Korsinsky, LLP, The Gross Law Firm, and Bleichmar Fonti & Auld LLP, are currently seeking lead plaintiffs, with a registration deadline of September 22, 2026.